SCHEDULE: Aberdeen Group Discloses Stake in Quoin Pharmaceuticals

Aberdeen Group plc and abrdn Inc. have filed a Schedule 13G, reporting beneficial ownership of 75,000 American Depositary Shares in Quoin Pharmaceuticals, Ltd., representing 4.16% of the class.

Summary

• Aberdeen Group plc and abrdn Inc. have jointly filed a Schedule 13G, indicating their beneficial ownership of Quoin Pharmaceuticals, Ltd. securities.
• The filing reports a total of 75,000 American Depositary Shares (ADSs) beneficially owned, with each ADS representing thirty-five (35) Ordinary Shares.
• This holding constitutes 4.16% of the class of securities.
• Both entities share voting and dispositive power over these shares.
• The filing is an amendment, indicating a change or update to previous filings.
• The reporting persons certify that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it is a routine disclosure of beneficial ownership by institutional investors and does not provide new operational or financial information about the company itself.

Positives

• The filing clarifies the ownership stake of Aberdeen Group and abrdn Inc. in Quoin Pharmaceuticals, providing transparency for investors.
• The reporting persons confirm that the shares are held in the ordinary course of business, suggesting a passive investment approach rather than an attempt to gain control.

Negatives

• The filing does not contain any negative financial or operational information about Quoin Pharmaceuticals itself, as it is a disclosure of ownership by an external entity.

Risks

• As a Schedule 13G filing, it primarily concerns ownership and does not inherently detail operational risks of Quoin Pharmaceuticals. However, any significant change in ownership or voting power by large holders could be a factor for other investors to monitor.
• The filing does not specify the exact nature of the underlying clients on whose behalf abrdn Inc. holds the shares, which could introduce indirect risk if those clients have specific investment mandates or risk appetites.

Future Outlook

The filing does not contain forward-looking statements or guidance regarding Quoin Pharmaceuticals' future performance. It is a disclosure of current beneficial ownership.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11."

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors accumulating stakes in publicly traded companies. This filing indicates that Aberdeen Group and abrdn Inc. have taken a notable, though not controlling, position in Quoin Pharmaceuticals, aligning with typical investment strategies in the pharmaceutical sector where significant stakes are often held by asset managers.

Stakeholder Impact

• Shareholders: Provides transparency on significant institutional ownership, which can influence market perception and potential future corporate actions.
• Management of Quoin Pharmaceuticals: Awareness of substantial passive holdings by major financial institutions.
• Potential Investors: The filing indicates a level of institutional interest in Quoin Pharmaceuticals.

Next Steps

• Investors may monitor future filings by Aberdeen Group plc and abrdn Inc. for any changes in their beneficial ownership of Quoin Pharmaceuticals.
• Further analysis of Quoin Pharmaceuticals' own SEC filings would be necessary to understand the company's performance and outlook.

Key Dates

Keywords

Schedule 13G, Quoin Pharmaceuticals, Aberdeen Group plc, abrdn Inc., American Depositary Shares, beneficial ownership, 4.16%, investment holding, SEC filing